TMX Newsfile Psychedelics News Releases

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression

Fri, 16 Oct 2026 08:55:00 -0400

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.Filament will offer regulatory support and update on the program's progress towards regulatory approval.Toronto, Ontario--(Newsfile Corp. - October 16, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing...

Doseology Announces Resignation of Director

Wed, 14 Oct 2026 18:00:00 -0400

Kelowna, British Columbia--(Newsfile Corp. - October 14, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that Larry Latowsky has resigned as a director of the Company, effective immediately.About Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)Doseology Sciences Inc. specializes in pouch-based oral stimulant and...

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Wed, 14 Oct 2026 08:34:00 -0400

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.Toronto, Ontario--(Newsfile Corp. - October 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company...

Entheon Announces Continuance into British Columbia

Thu, 08 Oct 2026 18:49:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's annual general and special meeting of...

Psyched Wellness Announces Secured Term Loan

Thu, 08 Oct 2026 17:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCID: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregate principal amount of US$110,577 (the "Loan")....

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV

Thu, 08 Oct 2026 08:19:00 -0400

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition with no approved medication.Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its...

Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer

Fri, 02 Oct 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 2, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics" or the "Company") is pleased to announce the appointment of J. David Warren, Ph.D., as Chief Executive Officer and as a director of the Company, effective October 1st, 2026.Dr. Warren brings more than two decades of experience in bioorganic chemistry, medicinal chemistry, peptide science and translational drug discovery. He is an Adjunct Associate Professor of Research in...

Numinus Wellness Founders to Resume Original Executive Roles

Thu, 01 Oct 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that its founders will resume their original executive leadership roles, effective October 1, 2026.Payton Nyquvest, founder and Executive Chair, will return to the role of Chief Executive Officer...

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence

Tue, 29 Sep 2026 07:53:00 -0400

Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health...

Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement

Mon, 28 Sep 2026 16:40:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce that, further to its news release dated August 14, 2026, the Company has closed its oversubscribed non-brokered private placement of 4,087,500 common shares (the "Shares") at a price of $0.08 per Share for aggregate gross proceeds of $327,000 (the "Private Placement"). The Company had originally announced the Private Placement for gross...